Animace načítání

Stránka se připravuje...


Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

Právní předpis byl sestaven k datu 17.04.2026.

Zobrazené znění právního předpisu je účinné od 28.01.2025.


Sdělení Ministerstva zahraničních věcí, kterým se mění a doplňují sdělení Ministerstva zahraničních věcí č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

19/2025 Sb.
 

Sdělení

INFORMACE

19

XXXXXXX

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,

xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx věcí č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
&xxxx;

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx sděluje, xx xxx 1. xxxxx 2023 xxxx generální xxxxxxxxxx UNESCO xxxxxxxx xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx x metod dopingu xxx xxx 2024 - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx proti xxxxxxx xx xxxxxx.

X xxxxx xxxxxx Přílohy X xxxxxxxx xxxxxxx Xxxxxxxxx České republiky x xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxx x xxxxxxx xxxx Xxxxxxx X Českou xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx X xxxxxxxxx x platnost x xxxxxxx x článkem 34 odst. 3 Xxxxxx xxx 1. xxxxx 2024, xxx Xxxxxx republiku xxxxxxxxx x platnost dne 18. xxxxxx 2024 x nahradilo Xxxxxxx X xxx xxx 2023, xxxxxxx xx 1. ledna 2023, xxxxx vstoupila v xxxxxxxx xxx Xxxxxx xxxxxxxxx xxx 22. xxxxxx 2023 a xxxx xxxxxxxxx pod č. 32/2023 Sb. m. s.

Xxxxxxxx xxxxx Přílohy X xxx rok 2024 a xxxx xxxxxxx do xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.
&xxxx;

Xxxxxxx:

x z. XXXx. Xxxxxx, Ph.D., XX.X., x. x.

xxxxxx xxxxxxx xxxxx xxxxxx a xxxxxxxxxx
&xxxx;

Xxxxxxx x. 1

Xxxxxxx xxxxxxxxxxx smlouvy do xxxxxxx xxxxxx

Xxxx

Xxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx xx xxxxxxx Xxxxxxxxxxx xxxxxxxx v xxxxx Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx.

Xxxxxx xx xxxxxxxxxx xxxxxxxxxxxx po xxxxxxxxx xxxxxxxxxxxx procesu zprostředkovaném Xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx (XXXX). Xxxxxx je xxxxxx xx 1. xxxxx 2024.

Oficiální text Xxxxxxx xxxxxxxxxx látek x xxxxx xxxx xxxxxxxxx WADA x xxxx xxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxxxxx. X případě xxxxxxxxxxx xxxxxxxxxxxxx xxxx anglickým x xxxxxxxxxxxx xxxxxx xxxxxxxxx znění v xxxxxxxxxx.

Xxxx xxxx xxxxxxx xxxxxxx xxxxx používané x xxxxx Xxxxxxx xxxxxxxxxx xxxxx x xxxxx.

Xxxxxxxx Xxx xxxxxxx

Xxxxx XXXX xxx xxxx xxxxx neschválila xxxx xxxxxx, je období Xxx xxxxxxx v xxxxxx xxxxxxx xxxxxxxxxxx xxxxx před xxxxxxx (xx 23:59 xxxxx) x xxx xxxxxxxxxxxxx Xxxxxxx, xxxxx xx xx Xxxxxxxxx xxxxxxxxx, xx xx xxxxx Xxxxxxx a xxxxxxx xxxxxx Xxxxxx.

Xxxxxxxx stále

To xxxxxxx, xx xxxx xxxxx nebo xxxxxx xx xxxxxxxx Xxx xxxxxxx x Xxxx xxxxxx, xxx xx xxxxxxxxxx v Xxxxxx.

Xxxxxxxxxx x Xxxxxxxxxxxx

Xxxxx xxxxxx 4.2.2 Xxxxxxxxx antidopingového Xxxxxx „xxx xxxxx xxxxxxxx xxxxxx 10 xxxxx všechny Zakázané xxxxx Xxxxxxxxxxxx látkami, x výjimkou xxxx xxxxxxxxxx x Xxxxxxx xxxxxxxxxx xxxxx a xxxxx dopingu. Xxxxx Xxxxxxxx metoda nebude Xxxxxxxxxxx xxxxxxx, xxxxx xxxx x Xxxxxxx xxxxxxxxx xxxxxxxx jako Xxxxxxxxxx metoda.“ Podle xxxxxxxxx x článku „Xxxxxxxxxx xxxxx x Xxxxxxxxxx metody xxxxxxx x článku 4.2.2 xx xxxxxx xxx xxxxxx způsobem xxxxxxxxxx xx xxxx xxxxxxxx xxxx méně xxxxxxxxxx xxx jiné dopingové xxxxx nebo xxxxxx. Xxx spíše x xxxxx x xxxxxx, xxxxx Xxxxxxxxx xxxxxxxxxxxxx xxxx xxxx xxxxxx x xxxxxx účelu xxx ke xxxxxxxx xxxxxxxxxxx xxxxxx.“

Xxxxxxxx látky

Podle xxxxxx 4.2.3 Kodexu xxxx Xxxxxxxx látky xxxxxxxxxx xxxx látky, xxxxx jsou xxxx xxxxxx xxxxxxxx x xxxxxx xxxxxx xxxxxxx xxxxxxxxxx ve xxxxxxxxxxx xxxx xxxxx sportu. Xxxx Xxxxxxxx látky xxxx xxxxxxxxxx tyto xxxxx: xxxxxx, xxxxxxxxx (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (THC).

S0 NESCHVÁLENÉ XXXXX

XXXXXXXX STÁLE (PŘI XXXXXXX X XXXX XXXXXX)

Xxxxxxx zakázané xxxxx x xxxx xxxxx xxxx Specifické látky.

Jakákoliv xxxxxxxxxxxxxx látka, xx xxxxxx xx nevztahuje xxxxx x xxxxxxxxxxxxx xxxxxx Seznamu x xxxxx není x xxxxxxxx xxxx xxxxxxxxx xxxxxx vládním xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxx xxxxxxx xxxxxxx x xxxx (např. xxxxxx x xxxxxxxxxxxxx nebo xxxxxxxxx vývoji xxxx xxxxxxx xxxxx xxx xxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxx xxx veterinární použití), xx xxxxxxxx xxxxx.

Xxxx xxxxx xxxxxxxx mnoho xxxxxxx xxxxx, xxxx xxxx BPC-157, 2,4-xxxxxxxxxxxx (XXX) x xxxxxxxxxx xxxxxxxxx (xxxx. Xxxxxxxxxxx x Tirasemtiv).

S1 ANABOLICKÉ XXXXX

XXXXXXXX STÁLE (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx zakázané xxxxx x této xxxxx xxxx Nespecifické xxxxx.

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

X1.1. XXXXXXXXXX ANDROGENNÍ XXXXXXXX (XXX)

Xxx xxxxxxxxx xxxxxx, xxxx xxxx xxxxxx:

1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-diol)

           

 • 

formebolon

1-androstenedion (5ɑ-xxxxxxx-1-xx-3,17-xxxx)

&xxxx;•

xxxxxxxxx (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx)

1-xxxxxxxxxxx (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx)

&xxxx;•

xxxxxxxxx

1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx)

&xxxx;•

xxxxxxxxxx

1-xxxxxxxxxxx (17ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-3-xx)

&xxxx;•

xxxxxxxxxx

4-xxxxxxxxxxxxxx (xxxxxxx-4-xx-3ß, 17ß-xxxx)

&xxxx;•

xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxxx-1,4-xxxx-3-xx)

4-xxxxxxxxxxxxxxxxxx(4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx)

&xxxx;•

xxxxxxxxx

5-xxxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)

&xxxx;•

xxxxxxxxxx

7ɑ-xxxxxxx-XXXX

&xxxx;•

xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx)

7ß-xxxxxxx-XXXX

&xxxx;•

xxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxx-5ɑ-xxxxxxx-1-xx-3-xx)

7-xxxx-XXXX

&xxxx;•

xxxxxxxxxxxxxx

11ß-xxxxx-19-xxxxxxxxxxxxxx

&xxxx;•

xxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx)

17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx)

&xxxx;•

xxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxx-4-xx-3-xx)

19-xxxxxxxxxxxxxxxxx (estr-4-en-3,17-diol)

 •

metyltestosteron

19-norandrostenedion (xxxx-4-xx-3,17-xxxx)

&xxxx;•

xxxxxxxxxx (metyltrienolon, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)

Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx)

&xxxx;•

xxxxxxxxx

xxxxxxxxxxxxx (5ɑ-dihydrotestosteron, 17ß-hydroxy-5ɑ-androstan-3-on)

 •

nandrolon (19-xxxxxxxxxxxxxx)

xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx)

&xxxx;•

xxxxxxxxxx

xxxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx)

&xxxx;•

xxxxxxxxxxxx (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx)

xxxxxxxxxx

&xxxx;•

xxxxxxxxxxxxx

xxxxxxxx

&xxxx;•

xxxxxxxx

xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx)

&xxxx;•

xxxxxxxxxx

xxxxxxxxxx

&xxxx;•

xxxxxxxxxxx

xxxxxxxxx

&xxxx;•

xxxxxxxxxx

xxxxxxx ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx)

&xxxx;•

xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3β-xxxxxxxxxxxxxx-5-xx-17-xx)

xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxx-1,4-xxxx-3-xx)

&xxxx;•

xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx)

xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx a 17ɑ-xxxxx-5ɑ- androst-3-en-17ß- xx)

&xxxx;•

xxxxxxxxx

xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx)

&xxxx;•

xxxxxxxxxx

xxxxxxxxxxx

&xxxx;•

xxxxxxxxx

xxxxxxxxxxxxxx (3β-hydroxy-5α-androstan-17-on)

 •

testosteron

epi-dihydrotestosteron (17β-hydroxy-5β-androstan-3-on)

 •

tetrahydrogestrinon (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx)

xxxxxxxxxxxxxx

&xxxx;•

xxxxxxx

xxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx)

&xxxx;•

xxxxxxxxx (17β-hydroxyestr-4,9,11-trien-3-on)

fluoxymesteron

 •

trestolon (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, XXXX)

x xxxxx xxxxx s xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X1.2. XXXXXXX ANABOLICKÉ XXXXX

Xxxx xxxx xxxxxx:

Xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, selektivní modulátory xxxxxxxxxxxxx receptorů [SARM, xxxx. xxxxxxx, enobosarm (xxxxxxx), XXX-4033 (xxxxxxxxx), XXX140, S-23 x XX-11], xxxxxxx a xxxxxxxxxx.

X2 XXXXXXXXX HORMONY, XXXXXXX XXXXXXX, PŘÍBUZNÉ XXXXX X XXXXXXXX

XXXXXXXX XXXXX (XXX SOUTĚŽI X MIMO XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx xxxxx x xxxxx látky x podobnou xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx účinky jsou xxxxxxxx.

X2.1. XXXXXXXXXXXXX (EPO) X XXXXX XXXXXXXXXXX XXXXXXXXXXX

Xxxx xxxx včetně:

S2.1.1 Xxxxxxxx erytropoetinových xxxxxxxxx, xxxx. xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (XXX); xxxxxxxxxx xxxxxxxx xx EPO, [xxxx. EPO-Fc, metoxypolyetylenglykol-epoetin xxxx (XXXX)]; XXX- xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxxxxxxx, např. XXXX-530, xxxxxxxxxxx.

X2.1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxx; xxxxxxxxxxx (XXX1278863); XXX2; xxxxxxxxxx (XXX 85-3934); xxxxxxxxxx (XX-4592); xxxxxxxxxx (XXX-6548); xenon.

S2.1.3 Xxxxxxxxxx XXXX, xxxx. X-11706.

X2.1.4 Xxxxxxxxxx signalizace xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxx (XXX-β), xxxx. xxxxxxxxxxxx; xxxxxxxxxxx.

X2.1.5 Xxxxxxxx xxxxxxxxx xxxxxxxxx receptoru, xxxx. asialo EPO; xxxxxxxxxxxxx EPO (CEPO).

S2.2. XXXXXXXXX XXXXXXX X XXXXXX XXXXXXXXXX XXXXXXX

X2.2.1 Xxxxxxx xxxxxxxxxxx xxxxxxxxxxx x xxxx, xxxx xxxx xxxxxx:

• choriový xxxxxxxxxxxx (XX),

• xxxxxxxxxxxx xxxxxx (XX),

• hormon xxxxxxxxxx xxxxxxxxxxxx (XxXX, xxxxxxxxxxx) x xxxx xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, leuprorelin, xxxxxxxxx x triptorelin),

 • xxxxxxxxxx x jeho xxxxxxxxxxx xxxxxxx.

X2.2.2 Xxxxxxxxxxxxxx a xxxxxx uvolňující xxxxxxx, xxxx. xxxxxxxxxxxx a xxxxxxxxxxxxx.

X2.2.3 Xxxxxxx xxxxxx (XX), xxxx xxxxxxx x fragmenty, xxxx xxxx xxxxxx:

• xxxxxxx xxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxx,

• xxxxxxxxx růstového xxxxxxx, xxxx. XXX-9604 x hGH 176–191.

X2.2.4 Xxxxxxx xxxxxxxxxx xxxxxxx xxxxxx, mimo xxxx xxxxxx:

• hormon xxxxxxxxxx xxxxxxx hormon (XXXX) x jeho analogy, xxxx. XXX-1293, XXX-1295, xxxxxxxxxx a xxxxxxxxxxx,

• xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX) a jejich xxxxxxxx [xxxx. xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx (XX-677), xxxxxxxxxx, lenomorelin (ghrelin), xxxxxxxxxxx x tabimorelin],

• xxxxxxx xxxxxxxxxx XX (XXXX) [např. xxxxxxxxxxxx, xxxxxxxxxx (xxxxxxxxx), XXXX-1, XXXX-2 (pralmorelin), GHRP-3, XXXX-4, XXXX-5 x XXXX-6].

X2.3. XXXXXXX FAKTORY X XXXXXXXXXX XXXXXXXXX XXXXXXX

Xxxx xxxx xxxxxx:

• xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• xxxxxxxxxxxx růstový xxxxxx (XXX)

• xxxxxxx xxxxxx 1 xxxxxxx xxxxxxxx (XXX-1, mecasermin) x xxxx analogy

• xxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• xxxxxxx xxxxxx xxxxxxxx x krevních xxxxxxxx (XXXX)

• xxxxxxxx-β4 x xxxx xxxxxxxx, xxxx. XX-500

• xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (VEGF)

a xxxxx růstové xxxxxxx xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx/xxxxxxxxx xxxxxxxx xx svalech, xxxxxxxx xxxx xxxxxx, xxxxxxxxxxxxx, využití energie, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx typy xxxxxxxxx xxxxxx.

X3 XXXX-2 AGONISTÉ

ZAKÁZANÉ XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxxx x xxxxxxxxxxxx xxxx-2 xxxxxxxx xxxxxx xxxxx xxxxxxxxx izomerů jsou xxxxxxxx.

Xxxx xxxx xxxxxx:

xxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx (xxxxxxxxxxxxx)

xxxxxxxxx

xxxxxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

XXXXXXX

• Xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 600 mikrogramů xxxxx 8 hodin xx jakékoliv xxxxx;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx xxxxxx xxxxx 54 xxxxxxxxxx za 24 xxxxx;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx;

• xxxxxxxxx xxxxxxxxxx: maximálně 25 xxxxxxxxxx xx 24 hodin.

POZNÁMKA

Přítomnost salbutamolu x xxxx v xxxxxxxx xxxxxx xxx 1000 xx/xx xxxx xxxxxxxxxxx v xxxxxxxx xxxxxx xxx 40 xx/xx neodpovídá terapeutickému xxxxxxx xxxxx a xxxx xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), pokud Xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, že xxxxxxxxxx xxxxxxxx xxx důsledkem xxxxxxxxxxxx xxxxx (inhalační) xx xx xxxx xxxxxxx xxxxxxxxx dávky.

S4 XXXXXXXXX A XXXXXXXXXXX XXXXXXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX I XXXX XXXXXX)

Xxxxxxxx xxxxx xx xxxxxxx X4.1 x X4.2 xxxx Xxxxxxxxxx xxxxx.

Xxxxx xxxxxxxx xx xxxx S4.3 x X4.4 xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx hormonové x xxxxxxxxxxx modulátory xxxx xxxxxxxx.

X4.1. XXXXXXXXXX XXXXXXXX

Xxxx xxxx xxxxxx:

2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)

xxxxxxxx-1,4,6-xxxxx-3,17-xxxx (xxxxxxxxxxxxxxxxx)

2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)

xxxxxxxx-3,5-xxxx-7,17-xxxx (xxxxxxxxx)

3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)

xxxxxxxxx

3-xxxxxxxxxxx (5ɑ-androst-3-en-17-on)

formestan

4-androsten-3,6,17 xxxxx (6-xxx)

xxxxxxxx

xxxxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

X4.2. ANTIESTROGENNÍ LÁTKY [XXXXXXXXXXXXX X XXXXXXXXXX XXXXXXXXXX XXXXXXXXXXXXX RECEPTORŮ (XXXXX)]

Xxxx xxxx xxxxxx:

xxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx (xxxxxxxxxxxxx)

xxxxxxxxx

xxxxxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

X4.3. LÁTKY XXXXXXXXXXX XXXXXXXX XXXXXXXXX XXXXXXXX XXX

Xxxx xxxx xxxxxx:

xxxxxxxxxx xxxxxxxxxxxxxx aktivin A

inhibitory xxxxxxxxxx, xxxx.:

xxxxxxxxxx receptoru xxxxxxxx IIB, xxxx.:

- xxxxx snižující xxxx xxxxxx xxxxxxx myostatinu

- xxxxxxx receptory aktivinu (xxxx. XXX-031)

- xxxxxxxx xxxxxx myostatin (xxxx. xxxxxxxxxxx, xxxxxxxxx xxxxxxxxxx)

xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx XXX (xxxx. xxxxxxxxxx)

- xxxxxxxxxx xxxxxxxxxxxxxx myostatin xxxx prekurzory (xxxx. xxxxxxxxxxx, xxxxxxx xxxxx, xxxxxxxxxxxxx, stamulumab)

S4.4. METABOLICKÉ XXXXXXXXXX

X4.4.1 aktivátory XXX-xxxxxxxxxx xxxxxxxxxxxxx (AMPK), např. XXXXX, xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxx aktivovaného receptoru xxxxx (XXXXδ), xxxx. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (xxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxx)xxxxxx) xxxxxxxx xxxxxx (XX1516, XX501516) x xxxxxxxx Rev-erbɑ , xxxx. XX9009, XX9011

X4.4.2 xxxxxxxx a xxxxxxxx xxxxxxxx

X4.4.3 meldonium

S4.4.4 xxxxxxxxxxxx

X5 XXXXXXXXX A XXXXXXXXX XXXXX

XXXXXXXX XXXXX (XXX SOUTĚŽI X XXXX XXXXXX)

Xxxxxxx zakázané xxxxx v xxxx xxxxx jsou Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxx a xxxxxxxxx látky, xxxxxx xxxxx optických xxxxxxx, xxxx. x- x x-, xxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

•&xxxx; Diuretika, xxxx xxxx.:

xxxxxxxxxxxx; amilorid; xxxxxxxxx; xxxxxxxx; chlortalidon; xxxxxxxx etakrynová; furosemid; xxxxxxxxx; metolazon; xxxxxxxxxxxxx; xxxxxxxx, např. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx a xxxxxxxxxxxxxxxxxx; xxxxxxxxx; triamteren;

• Vaptany, xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx;

• Xxxxxxxxxxx expandéry xxxxxxxx xxxxxxxxxxxx, xxxx.:

xxxxxxx, xxxxxxx, xxxxxxxxxxx škrob, xxxxxxxx;

• Xxxxxxxxxxx;

• Xxxxxxxxxx;

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou xxxx podobnými biologickými xxxxxx.

XXXXXXX

• xxxxxxxxxxx; xxxxxxxx; x xxxxxxx xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx karboanhydrázy (xxxx. dorzolamid, xxxxxxxxxxx);

• xxxxxxx podání felypresinu x xxxxx xxxxxxxxx.

XXXXXXXX

Xxxxx xxxxxxxxxxx xxxxxxxx látky xx xxxxxxxxxx xxxxxxxx xxxxxxx: x xxxxxxxxxxx, xxxxxxxxxxx, katinu, xxxxxxxx, xxxxxxxxxxxxx x pseudoefedrinu xx Xxxxxx Sportovce xxxxxxxx nebo xxxxxxxx Xxx Xxxxxxx ve xxxxxxx s xxxxxxxxxx xxxx jinou xxxxxxxxx xxxxxx (kromě xxxxxxxxx xxxxxx podání inhibitoru xxxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx), xxxx xxxxxxxxx xx Pozitivní xxxxxxxxxxx nález (XXX), xxxxx Xxxxxxxxx nemá xxxxxxxxxx Terapeutickou xxxxxxx (XX) xx xxxx xxxxx xxxxx x xx, xxxxx xxx xxxx udělena xx xxxxxxxxxx nebo xxxxx xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

XXXXXXXX XXXXX (XXX SOUTĚŽI X XXXX SOUTĚŽ)

Všechny xxxxxxxx metody x xxxx třídě jsou Xxxxxxxxxxxx x xxxxxxxx xxxxx x X2.2, xxx jsou Specifické xxxxxx.

X1. XXXXXXXXXX X XXXX X XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X1.1. Xxxxxx nebo opětovné xxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, xxxxxxxxx (xxxxxxxxx) xxxx heterologní xxxx xxxx xxxxxxxx z xxxxxxxxx krvinek xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx s xxxxxxxx xxxxxxxx plazmy nebo xxxxxx xxxxxx Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxx provedené x registrovaném xxxxxxxxx xxxxxx.

X1.2. Xxxxx zvyšování xxxxxx, přenosu xxxx xxxxxxx xxxxxxx.

Xxxx jiné xxxxxx:

Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (XXX13); xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, např. xxxxxx xxxxxxxx na xxxx hemoglobinu x xxxxxxxxxxxxxxxx hemoglobinové xxxxxxxx, x xxxxxxxx xxxxxxxxxxx xxxxxxx inhalací.

M1.3. Jakákoliv xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx nebo x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.

X2. XXXXXXXX X XXXXXXXXX MANIPULACE

Zakázané xx xxxxxxxxxxx:

X2.1. Xxxxxxxxx xxxx Xxxxx x podvod xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxx x/xxxx xxxxxx Xxxxxx, xxxx. xxxxxxxx xxxxxxx ke Vzorku.

M2.2. Xxxxxxxxxx infuze x/xxxx xxxxxxx více než xxxxxx 100 xx xx 12 xxxxx xxxxx infuzí legitimně xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxxx, xxxxxxxxxxxxx xxxxxxx xxxx klinických xxxxxxxxxxxxxx xxxxxxxxx.

X3. XXXXXX X BUNĚČNÝ DOPING

Z xxxxxx potencionálního xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:

X3.1. Xxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxx, xxxxx xxxxx změnit xxxxxxxx xxxxxx x/xxxx exprese xxxx xxxxxxxxxx xxxxxxxxxxx. Xx xxxx jiné xxxxxxxx xxxxxxxxxxx xxxxx xxxx, umlčování xxxx x xxxxxxxxxxx xxxxxxx xxxx.

X3.2. Xxxxxxx normálních xxxx geneticky xxxxxxxxxxxxxx xxxxx.

X6 STIMULANCIA

ZAKÁZANÉ XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Specifické xxxxx x výjimkou xxxxx xxxxxxxxx x X6.X, xxx jsou Xxxxxxxxxxxx xxxxx.

Xxxxxxxx xxxxx x xxxx xxxxx: xxxxxx x xxxxxxxxxxxxxxxxxxxxxxxx (MDMA/„extáze“)

Všechna xxxxxxxxxxx, xxxxxx všech xxxxxxxxx izomerů, xxxx. x- x x-, xxxx xxxxxxxx.

Xxxxxxxxxxx xxxxxxxx:

X6.X: XXXXXXXXXXXX STIMULANCIA

adrafinil

fonturacetam [4-fenylpiracetam (xxxxxxxx)]

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxxx

xxxxxxxxxxxxxxx

xxxxxxxxxxxx(x-)

xxxxxxxxx

x-xxxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxx

xxxxxx

xxxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxxx

Xxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxx x xxxxx xxxxxx, xx Xxxxxxxxxxx xxxxxx.

X6.X: SPECIFICKÁ XXXXXXXXXXX

Xxxx xxxx xxxxxx:

2-xxxxxxxxxxx-1-xxxx (ß-xxxxxxxxxxxxxx-xxxx, XXXXX)

xxxxxxxxxxx

xxxxxxxxx

3-xxxxxxxxxx-2-xxxx (1,2-xxxxxxxxxxxxxxxxx)

xxxxxxxxxxx

xxxxxxxxx (xxxxxxxxxxxxx)

4-xxxxxxxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxx

4-xxxxxxxxxx-2-xxxx (1,3-dimetylamylamin, 1,3 XXXX, xxxxxxxxxxxxxx)

xxxxxxxxxx

xxxxxxxxxxx

4-xxxxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxxxx)

xxxxxxxxxx (xxxxxxxxx)

xxxxxxxxxxx a xxxx xxxxxxxx

5-xxxxxxxxxx-2-xxxx (1,4-xxxxxxxxxxxxxxx, 1,4-xxxxxxxxxxxxxxxxx, 1,4-XXXX)

xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx)

xxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxxxx

xxxxxxxxxxxxx

xxxxx1)

xxxxxxxxxxxxxxx

xxxxxxxxxxxxxx

xxxxxxx x xxxx xxxxxxx, např. xxxxxxxx, metedron x ɑ-xxxxxxxxxxxxxxxxxxxxxx

xxxxxxxxxxxx

xxxxxxxxxxxxx2)

xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx)

xxxxxxxxxxxxxxxxxxxxxxxx

xxxxxxxxx

xxxxxxx3)

xxxxxxxxxxxx3)

xxxxxxxxxx

xxxxxxxxx (xxxxxxxxx)4)

xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- xx)xxxxxx]

xxxxxxxxxxxx

xxxxxxxx

xxxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx)

xxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxxxxx

xxxxxxxxx

xxxxxxxx (1,5-xxxxxxxxxxxxxxxx)

x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx

XXXXXXX

• xxxxxxxx;

• xxxxxxxx xxxxxxxxxxx v xxxxxxx xxxxxx xxxxxxx, xxxxxxx, xxxxxx nebo xxxxxx xxxxxxx (xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxx) x stimulancia zařazená xx Monitorovacího xxxxxxxx 20245).

X7 NARKOTIKA

ZAKÁZANÉ XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxx látky.

Návykové xxxxx v této xxxxx: xxxxxxxxx (xxxxxx)

Xxxxxxxxxxx xxxxxxxxx, xxxxxx jejich xxxxxxxxxx všech xxxxxxxxx xxxxxxx, xxxx. x- x x, jsou xxxxxxxx.

xxxxxxxxxxx

xxxxxxxx a jeho xxxxxxxx

xxxxxx

xxxxxxxxxx

xxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxx

xxxxxxxxx (heroin)

metadon

oxykodon

tramadol

oxymorfon

S8 XXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx zakázané xxxxx x xxxx xxxxx jsou Xxxxxxxxxx xxxxx. Xxxxxxxx xxxxx x xxxx sekci: xxxxxxxxxxxxxxxxxxx (XXX)

Xxxxxxx xxxxxxxx x xxxxxxxxxx xxxxxxxxxxx xxxx zakázané, xxxx.

• x konopí (xxxxx, xxxxxxxxx) x konopných xxxxxxxxxx

• přírodní x xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx (THC)

• xxxxxxxxxx xxxxxxxxxxx napodobující xxxxxx XXX

XXXXXXX

• kanabidiol

S9 XXXXXXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx látky.

Všechny xxxxxxxxxxxxxxx xxxx xxxxxxxx, xxxxx xxxx podávány xxxxxxxxxx xxxxxxxx, xxxxxxxxx [xxxxxx xxxxxxxxxx (např. xxxxxxx, xxxxxxxxxx, sublingvální)] nebo xxxxxxxx xxxxxx.

Xxxx xxxx xxxxxx:

xxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxxx xxxxxxxx

xxxxxxxx

xxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxxxxxxxx

XXXXXXXX

• Xxxx xxxxxxx xxxxxx (včetně xxxxxxxxxxx x topického: xxxxxxxx-xxxxxxxxxxxxxx, dermálního, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, ušního a xxxxxxxxxxxx) nejsou xxxxxxxx, xxxxx xx xxxxxxxxx x rámci výrobcem xxxxxxxxxxxx dávek a xxxxxxxxxxxxxx xxxxxxxx.

X1 XXXX-XXXXXXXXX

XXXXXXXX X URČITÝCH SPORTECH

Všechny xxxxxxxx látky x xxxx třídě xxxx Xxxxxxxxxx xxxxx.

Xxxx-xxxxxxxxx xxxx xxxxxxxx pouze x xxxxxxxxxxxxx sportech Xxx Xxxxxxx x kde xx xx xxxxxxxx xxxxxxxx (*) x Xxxx soutěž.

• lukostřelba (XX)*

• lyžování/snowboarding (XXX) – xxxxx xx xxxxxx, akrobatické xxxxx / X-xxxxx a xxxxxxxxx X-xxxxx / xxx xxx

• xxxxxxxxxxxx xxxxx (FIA)

• podvodní xxxxxx (XXXX)* v xxxxxxxxxxxx xxxxxxx potápění, xxxx xxxxxxxx x xxxxxxx xx xxxx

• xxxxxxxx (xxxxxxx disciplíny) (XXXX)

• xxxxx (WDF)

• xxxx (XXX)

• xxxxxxxx (XXX)

• střelba (XXXX, XXX)*

* zakázané také Xxxx soutěž

Mimo xxxx xxxxxx:

xxxxxxxxxx

xxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxxxxxx

xxxxxxxx

xxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxx

xxxxxxx

xxxxxxxxxx

xxxxxxx

xxxxxxxxx

xxxxxxx

Xxxxxxx č. 2

Xxxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxx xxxxxx
&xxxx;

1) xxxxx (x-xxxxxxxxxxxxxxxx) a xxxx x-xxxxxx: je zakázaný xxxxx xxx koncentraci x xxxx vyšší xxx 5 mikrogramů x 1 xx.

2) xxxxxxxxxxxxx: xxxxxxxx xxxxx xxx koncentraci x xxxx vyšší xxx 150 mikrogramů x 1 xx.

3) xxxxxxx x xxxxxxxxxxxx: xxxxxxxx xxx xxxxxxxxxxx x xxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx.

4) xxxxxxxxx (xxxxxxxxx): není xxxxxxxx xxxxxxx xxxxxxxx, xxxx. xxxxx, xxxx, xxxx xxxxxxxx xxxxxxxx x xxxxxxxxx anestetiky.

5) xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, pipradrol a xxxxxxxx: tyto látky xxxx zahrnuté xx Xxxxxxxxxxxxxx programu 2024 x xxxxxx považovány xx Xxxxxxxx látky.

Informace

Právní xxxxxxx x. 19/2025 Xx. nabyl xxxxxxxxx xxxx 28.1.2024.

Znění xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx právních předpisů x odkazech není xxxxxxxxxxxxx, xxxxx se xxxx xxxxxx xxxxxxxxx xxxxx xxxxx uvedeného xxxxxxxx předpisu